Bicycle Therapeutics price target lowered to $55 from $57 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Bicycle Therapeutics to $55 from $57 and keeps a Buy rating on the shares following the Q4 report. Bicycle ended 2023 with $526M of cash and cash equivalents, which is sufficient to run operations into 2026, the analyst tells investors in a research note.